Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Postoperative urinary retention is a frequent complication of spinal surgeries and impacts a large portion of this population which results in increased morbidity as a result of increased number of catheterizations, urinary tract infections (UTIs) and prolonged hospital stays. With the addition of Tamsulosin, the investigators would anticipate a reduction in the incidence and duration of postoperative urinary retention and therefore a reduction in morbidity related to treatment of urinary retention as well as shortened hospital stays.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Tamsulosin

Criteria

Inclusion Criteria

• ≥ 35 years (Males & Females)

• Cervical Laminectomy

• Cervical Posterior Fusion

• Cervical Anterior/Posterior Fusion

• Lumbar Laminectomy

• Lumbar Posterolateral Fusion

• Lumbar Interbody Fusion

Exclusion Criteria

• < 35 years

• Cervical Anterior Discectomy and Fusion

• Cervical Anterior Corpectomy

• Cervical Posterior Discectomy

• Cervical Foraminotomy

• Lumbar Discectomy (METRx or Open)

• Lumbar Foraminotomy

• Lumbar Anterior Fusion

• Myelopathy with bladder dysfunction

• Patients currently taking an alpha-antagonist

• Patients with history of allergy or sensitivity to tamsulosin or other alpha-antagonist (alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, and phenoxybenzamine)

• History of prostatectomy or urologic surgery involving the bladder or urethra

• Severe liver disease or end-stage renal disease

• Patients taking strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir/ritonavir, lopinavir/ritonavir, and conivaptan)

• Patients with a mental disability

• Prisoners